FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160982012> ?p ?o ?g. }

• W2160982012 endingPage "249" @default.
• W2160982012 startingPage "242" @default.
• W2160982012 abstract "Purpose To compare the toxicities, tumor control, survival, and quality of life of nasopharyngeal cancer (NPC) patients treated with sequential neoadjuvant chemotherapy followed by concurrent cisplatin-radiotherapy (CRT) or CRT alone. Patients and Methods Previously untreated stage III to IVB NPC were randomly assigned to (1) neoadjuvant docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 every 3 weeks for two cycles, followed by cisplatin 40 mg/m 2 /wk concurrent with radiotherapy, or (2) CRT alone. Planned accrual was 30 patients per arm to detect 20% difference of toxicities based on 95% CIs. Results From November 2002 to November 2004, 65 eligible patients were randomly assigned to neoadjuvant chemotherapy followed by CRT (n = 34) or CRT alone (n = 31). There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy. No significant differences in rates of acute toxicities were observed between the two arms during CRT. Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms. The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12). The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012). Conclusion Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT. Preliminary results suggested a positive impact on survival. A phase III study to definitively test this neoadjuvant-concurrent strategy is warranted." @default.
• W2160982012 created "2016-06-24" @default.
• W2160982012 creator A5005837271 @default.
• W2160982012 creator A5006443491 @default.
• W2160982012 creator A5006449106 @default.
• W2160982012 creator A5023364103 @default.
• W2160982012 creator A5033886818 @default.
• W2160982012 creator A5036729345 @default.
• W2160982012 creator A5052600455 @default.
• W2160982012 creator A5062767641 @default.
• W2160982012 creator A5065932794 @default.
• W2160982012 creator A5068970043 @default.
• W2160982012 creator A5079531819 @default.
• W2160982012 creator A5079759742 @default.
• W2160982012 creator A5085444884 @default.
• W2160982012 creator A5090863040 @default.
• W2160982012 date "2009-01-10" @default.
• W2160982012 modified "2023-09-28" @default.
• W2160982012 title "Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma" @default.
• W2160982012 cites W1569089611 @default.
• W2160982012 cites W1765857451 @default.
• W2160982012 cites W182988086 @default.
• W2160982012 cites W1854220427 @default.
• W2160982012 cites W1902822116 @default.
• W2160982012 cites W1939558678 @default.
• W2160982012 cites W1954454354 @default.
• W2160982012 cites W1976661936 @default.
• W2160982012 cites W1983970003 @default.
• W2160982012 cites W1984396523 @default.
• W2160982012 cites W1986529553 @default.
• W2160982012 cites W1987350106 @default.
• W2160982012 cites W1997391888 @default.
• W2160982012 cites W2005374110 @default.
• W2160982012 cites W2014166989 @default.
• W2160982012 cites W2015167754 @default.
• W2160982012 cites W2017030602 @default.
• W2160982012 cites W2043945205 @default.
• W2160982012 cites W2051367322 @default.
• W2160982012 cites W2051782451 @default.
• W2160982012 cites W2057724770 @default.
• W2160982012 cites W2075214861 @default.
• W2160982012 cites W2082401733 @default.
• W2160982012 cites W2084803897 @default.
• W2160982012 cites W2100957469 @default.
• W2160982012 cites W2106293343 @default.
• W2160982012 cites W2107115180 @default.
• W2160982012 cites W2111140446 @default.
• W2160982012 cites W2127706390 @default.
• W2160982012 cites W2141317222 @default.
• W2160982012 cites W2141592118 @default.
• W2160982012 cites W2145115983 @default.
• W2160982012 cites W2148900467 @default.
• W2160982012 cites W2151645021 @default.
• W2160982012 cites W2167571044 @default.
• W2160982012 cites W2167805334 @default.
• W2160982012 cites W2184400718 @default.
• W2160982012 cites W2290932069 @default.
• W2160982012 cites W2324392028 @default.
• W2160982012 cites W4242078395 @default.
• W2160982012 doi "https://doi.org/10.1200/jco.2008.18.1545" @default.
• W2160982012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19064973" @default.
• W2160982012 hasPublicationYear "2009" @default.
• W2160982012 type Work @default.
• W2160982012 sameAs 2160982012 @default.
• W2160982012 citedByCount "458" @default.
• W2160982012 countsByYear W21609820122012 @default.
• W2160982012 countsByYear W21609820122013 @default.
• W2160982012 countsByYear W21609820122014 @default.
• W2160982012 countsByYear W21609820122015 @default.
• W2160982012 countsByYear W21609820122016 @default.
• W2160982012 countsByYear W21609820122017 @default.
• W2160982012 countsByYear W21609820122018 @default.
• W2160982012 countsByYear W21609820122019 @default.
• W2160982012 countsByYear W21609820122020 @default.
• W2160982012 countsByYear W21609820122021 @default.
• W2160982012 countsByYear W21609820122022 @default.
• W2160982012 countsByYear W21609820122023 @default.
• W2160982012 crossrefType "journal-article" @default.
• W2160982012 hasAuthorship W2160982012A5005837271 @default.
• W2160982012 hasAuthorship W2160982012A5006443491 @default.
• W2160982012 hasAuthorship W2160982012A5006449106 @default.
• W2160982012 hasAuthorship W2160982012A5023364103 @default.
• W2160982012 hasAuthorship W2160982012A5033886818 @default.
• W2160982012 hasAuthorship W2160982012A5036729345 @default.
• W2160982012 hasAuthorship W2160982012A5052600455 @default.
• W2160982012 hasAuthorship W2160982012A5062767641 @default.
• W2160982012 hasAuthorship W2160982012A5065932794 @default.
• W2160982012 hasAuthorship W2160982012A5068970043 @default.
• W2160982012 hasAuthorship W2160982012A5079531819 @default.
• W2160982012 hasAuthorship W2160982012A5079759742 @default.
• W2160982012 hasAuthorship W2160982012A5085444884 @default.
• W2160982012 hasAuthorship W2160982012A5090863040 @default.
• W2160982012 hasConcept C121608353 @default.
• W2160982012 hasConcept C126322002 @default.
• W2160982012 hasConcept C143998085 @default.
• W2160982012 hasConcept C207103383 @default.
• W2160982012 hasConcept C2776694085 @default.
• W2160982012 hasConcept C2777063308 @default.

• next